Indian vaccines manufacturer Bharat Biotech has on Monday announced that the phase-1 first-in-human clinical trials of its indigenously developed Chikungunya vaccine are underway in the country to evaluate its safety, tolerability and immunogenicity.
In a statement, the company said “the placebo controlled study involving 60 healthy volunteers would test escalating doses of the vaccine in prime-boost regimen.”
